Pfizer’s Entrance into Orphan Drugs Adds to Genzyme’s Woes
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 12 (Table of Contents)
Published: 8 Dec-2009
DOI: 10.3833/pdr.v2009.i12.1282 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Pfizer has signed an agreement with Israeli company, Protalix, to develop and commercialise Uplyso (taliglucerase alfa), a novel proprietary plant cell-based enzyme replacement therapy for treatment of Gaucher’s disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS